Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035

Adlai Nortye (NASDAQ: ANL) announced that it has separately entered into clinical trial collaboration and drug supply agreements with Eli Lilly and Company (NYSE: LLY) and Merck KGaA, Darmstadt, Germany (ETR: MRK), for the anti‑EGFR antibody cetuximab (brand name ERBITUX) – supporting the company’s ongoing global Phase 1 clinical trial of AN4035, its first‑in‑class ADC targeting CEACAM5 with a highly active pan‑RAS(ON) inhibitor payload, in CEACAM5‑high, RAS‑dependent solid tumors.

Agreement Snapshot

Drug Profile & Mechanism of Action

• Molecule: AN4035 – a first‑in‑class antibody‑drug conjugate (ADC) targeting CEACAM5 (carcinoembryonic antigen‑related cell adhesion molecule 5), an antigen overexpressed in multiple solid tumors.
• Payload: Carries a highly active pan‑RAS(ON) inhibitor – designed to disable RAS signaling across mutant and wild‑form active states upon intracellular payload release, marrying targeted delivery with a next‑generation RAS‑pathway inhibitor.
• Combination Rationale: The trial evaluates AN4035 as both monotherapy and in combination with cetuximab, the established anti‑EGFR antibody – a pairing intended to probe complementary blockade of EGFR‑driven and RAS‑dependent signaling in solid tumors.
• Biomarker‑Driven Design: Enrollment focuses on CEACAM5‑high, RAS‑dependent tumors, aligning antigen expression and pathway dependence to maximize the probability of signal in early clinical evaluation.
• Trial Status: The global Phase 1 study is ongoing; safety, pharmacokinetic, and efficacy data were not disclosed in the announcement.

Partnership & Operational Context

• Sponsorship: Adlai Nortye is the sponsor of the clinical trial, retaining development control while partners contribute comparator/combination drug supply.
• Geographic Coverage: Under the agreements, Eli Lilly will provide cetuximab free of charge for clinical trial sites in the United States, and Merck KGaA, Darmstadt, Germany, will supply the drug free of charge for sites in Australia and China – matching ERBITUX’s regional commercial rights holders to the trial’s global footprint.
• Cost Efficiency: Free‑of‑charge supply of a branded combination partner reduces trial operating costs and streamlines site activation across three regions.

Market Impact & Outlook

• First‑in‑Class Positioning: AN4035’s combination of a CEACAM5‑targeted ADC with a pan‑RAS(ON) inhibitor payload places Adlai Nortye in a globally unoccupied niche at the intersection of two of oncology’s hottest modalities – ADCs and next‑generation RAS inhibitors.
• Big‑Pharma Validation: Collaboration agreements with Eli Lilly and Merck KGaA provide third‑party endorsement of the trial’s scientific design and facilitate combination evaluation with a standard‑of‑care anti‑EGFR backbone.
• Target Population: RAS‑dependent solid tumors – including colorectal, pancreatic, and lung cancers – represent large patient populations where resistance to existing RAS and EGFR therapies drives high unmet need.
• Key Catalysts: Phase 1 dose escalation, safety/tolerability readouts, and preliminary efficacy signals in CEACAM5‑high tumors will be the next value inflection points; timing not disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the clinical development, partnerships, and commercial potential of AN4035. Early‑stage candidates carry substantial risk of failure; actual results may differ due to trial outcomes, safety findings, regulatory requirements, and competitive dynamics. This summary is for informational purposes only and does not constitute investment advice.-Fineline Info & Tech